We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

34 hedge funds and large institutions have $1.94M invested in NeuBase Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

23% less funds holding

Funds holding: 44 → 34 (-10)

44% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 9

59% less capital invested

Capital invested by funds: $4.74M → $1.94M (-$2.8M)

77% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 13

Holders
34
Holders Change
-10
Holders Change %
-22.73%
% of All Funds
0.55%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
5
Reduced
9
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
E
Ergoteles
New York
+$9.72K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$9.72K
3
HF
HRT Financial
New York
+$4K
4
TRCT
Tower Research Capital (TRC)
New York
+$1.26K
5
Wells Fargo
Wells Fargo
California
+$1.03K

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$345K
2
SCM
Sio Capital Management
New York
-$102K
3
WVP
Worth Venture Partners
New Jersey
-$84K
4
JAMONY
Jacob Asset Management of New York
California
-$40.4K
5
Goldman Sachs
Goldman Sachs
New York
-$32K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$519K – – –
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$238K – – –
DCMIC
3
Decheng Capital Management III (Cayman)
Cayman Islands
$190K – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$180K -$29.1K -5,669 -11%
CMU
5
Carnegie Mellon University
Pennsylvania
$179K – – –
PAMP
6
Polar Asset Management Partners
Ontario, Canada
$121K – – –
KAS
7
Kestra Advisory Services
Texas
$96.9K – – –
CM
8
CM Management
Florida
$67K -$25.6K -5,000 -22%
JAMONY
9
Jacob Asset Management of New York
California
$59.6K -$40.4K -7,871 -33%
PCM
10
Prelude Capital Management
New York
$59.2K – – –
Renaissance Technologies
11
Renaissance Technologies
New York
$54K -$554 -108 -0.8%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$44K -$154 -30 -0.3%
WPW
13
Waldron Private Wealth
Pennsylvania
$31K – – –
PCM
14
Perkins Capital Management
Minnesota
$19K +$256 +50 +1%
BlackRock
15
BlackRock
New York
$14.1K +$318 +62 +2%
State Street
16
State Street
Massachusetts
$13.1K – – –
Northern Trust
17
Northern Trust
Illinois
$10.4K – – –
DC
18
Davenport & Co
Virginia
$7.7K – – –
E
19
Ergoteles
New York
$7.21K +$9.72K +1,895 New
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$7.21K +$9.72K +1,895 New
Charles Schwab
21
Charles Schwab
California
$5.65K – – –
TSS
22
Two Sigma Securities
New York
$3.36K -$3.67K -716 -45%
Bank of America
23
Bank of America
North Carolina
$3.05K -$10 -2 -0.2%
Mariner
24
Mariner
Kansas
$3K – – –
TRCT
25
Tower Research Capital (TRC)
New York
$3K +$1.26K +245 +38%
1
2

NBSE Hedge Fund Activity: Q4 2022 in Review

34 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2022, worth a combined $1.94M — down 59% from $4.74M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of NBSE and 3 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 5 added.

The largest buyer was Ergoteles, opening a new position worth an estimated $9.72K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $345K sold.

  • 34 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2022, down from 44 in Q3 2022.
  • Funds reported $1.94M of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2022, down 59% quarter-over-quarter.
  • 3 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2022 and 13 closed out, a net change of -10 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2022 was Ergoteles, an estimated $9.72K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2022 was AIGH Capital Management, an estimated $345K sold.

Based on aggregated 13F filings for Q4 2022.